Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is China Biologic Products Inc (CBPO) A Good Stock To Buy?

Out of thousands of stocks that are currently traded on the market, it might be really difficult to determine those that can really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs/PhDs, industry experts, and they are well connected to get tips from insiders. Individual investors can piggyback hedge funds and may be able to benefit from their vast resources. We analyze quarterly 13F filings of over 700 hedge funds and, by looking at the smart money sentiment that surrounds a stock, we can determine whether it has potential to beat the market over the long-term. Therefore, let’s take a closer look at what smart money thinks about China Biologic Products Inc (NASDAQ:CBPO).

China Biologic Products Inc (NASDAQ:CBPO) was in 19 hedge funds’ portfolios at the end of the third quarter of 2015. CBPO has seen a decrease in enthusiasm from smart money lately. There were 19 hedge funds in our database with CBPO holdings at the end of the previous quarter. At the end of this article we will also compare CBPO to other stocks, including Steven Madden, Ltd. (NASDAQ:SHOO), Eldorado Gold Corp (USA) (NYSE:EGO), and RLI Corp. (NYSE:RLI) to get a better sense of its popularity.

Follow China Biologic Products Inc. (NASDAQ:CBPO)
Trade (NASDAQ:CBPO) Now!

In the 21st century investor’s toolkit there are many metrics stock market investors can use to analyze stocks. Some of the most underrated metrics are hedge fund and insider trading moves. Our experts have shown that, historically, those who follow the best picks of the elite money managers can outpace their index-focused peers by a solid margin (see the details here).

Keeping this in mind, let’s take a gander at the new action regarding China Biologic Products Inc (NASDAQ:CBPO).

What does the smart money think about China Biologic Products Inc (NASDAQ:CBPO)?

At Q3’s end, a total of 19 of the hedge funds tracked by Insider Monkey were long in this stock, a change of 0% from one quarter earlier. With the smart money’s positions undergoing their usual ebb and flow, there exists a few noteworthy hedge fund managers who were boosting their stakes substantially (or already accumulated large positions).

According to Insider Monkey’s hedge fund database, Jacob Gottlieb’s Visium Asset Management had the biggest position in China Biologic Products Inc (NASDAQ:CBPO), worth close to $46.4 million, amounting to 0.6% of its total 13F portfolio. The second largest stake is held by Renaissance Technologies, managed by Jim Simons, which held a $34.9 million position; the fund has 0.1% of its 13F portfolio invested in the stock. Some other hedge funds that hold long positions consist of Bihua Chen’s Cormorant Asset Management, and John Overdeck and David Siegel’s Two Sigma Advisors.

Judging by the fact that China Biologic Products Inc (NASDAQ:CBPO) has faced bearish sentiment from the aggregate hedge fund industry, it’s easy to see that there exists a select few hedge funds that decided to sell off their positions entirely in the third quarter. Intriguingly, Ted Kang’s Kylin Management said goodbye to the largest stake of all the hedgies followed by Insider Monkey, totaling about $21.7 million in stock, and Joseph Edelman of Perceptive Advisors was right behind this move, as the fund dropped about $17 million worth. These bearish behaviors are important to note, as aggregate hedge fund interest stayed the same (this is a bearish signal in our experience).

Let’s now take a look at hedge fund activity in other stocks – not necessarily in the same industry as China Biologic Products Inc (NASDAQ:CBPO) but similarly valued. We will take a look at Steven Madden, Ltd. (NASDAQ:SHOO), Eldorado Gold Corp (USA) (NYSE:EGO), RLI Corp. (NYSE:RLI), and Medical Properties Trust, Inc. (NYSE:MPW). All of these stocks’ market caps match CBPO’s market cap.

Ticker No of HFs with positions Total Value of HF Positions (x1000) Change in HF Position
SHOO 18 134345 3
EGO 14 55138 -1
RLI 13 109257 4
MPW 10 72602 3

As you can see these stocks had an average of 13.75 hedge funds with bullish positions and the average amount invested in these stocks was $93 million.That figure was $154 millions in CBPO’s case. Steven Madden, Ltd. (NASDAQ:SHOO) is the most popular stock in this table. On the other hand Medical Properties Trust, Inc. (NYSE:MPW) is the least popular one with only 10 bullish hedge fund positions. Compared to these stocks China Biologic Products Inc (NASDAQ:CBPO) is more popular among hedge funds. Considering that hedge funds are fond of this stock in relation to the other companies analyzed in this article, it may be a good idea to analyze it in detail and potentially include it in your portfolio.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.